Repligen corp stock.

Dec 2, 2023 · With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ...

Repligen corp stock. Things To Know About Repligen corp stock.

Track Repligen Corp. (RGEN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 24, 2023 · In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements. Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...RGN:MUN Munich Stock Exchange; RGN:STU Stuttgart Stock Exchange; RGEN:DEU German Composite; RGN:FRA Frankfurt Stock Exchange; RGN:DUS Dusseldorf Stock Exchange; ... Repligen Corp BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM 02453 United States USA; Phone +1 (781) 449-9560; Fax +1 (302) …Track Repligen Corp. (RGEN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ...

RGEN - Repligen Corp. - Stock screener for investors and traders, financial visualizations.Repligen Corp (NASDAQ:RGEN) 157.02 Delayed Data As of Nov 21 +1.38 / +0.89% Today’s Change 110.45 Today ||| 52-Week Range 200.98 -7.26% Year-to-Date Quote …

The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,025 full-time employees.The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio.Repligen Corporation Stock price Equities RGEN US7599161095 Medical Equipment, Supplies & Distribution Summary Quotes Charts News Ratings Calendar …

The stock price rose by $0.27, resulting in a percentage change of +0.61%. While this may seem like a small change, it indicates positive momentum for the company’s stock. Looking ahead, Repligen Corporation is scheduled to release its next financial report on February 15, 2024.

Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...

Invest in Repligen Corp on Stash Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process.On Friday, Repligen Corp (RGEN:NSQ) closed at 161.78, -19.50% below its 52-week high of 200.98, set on Feb 16, 2023. Data delayed at least 15 minutes, as of Nov 24 2023 18:00 GMT. Latest Repligen Corp (RGEN:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist... Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected] SEC Filings - Repligen Corp.- Annual Report, Proxy Statement, Prospectus ... DEFINITIONS The name of the plan is the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other. 2008-08-08:Nov 30, 2023 · The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares.

Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ...Repligen Corp (RGEN) Stock Shows Promising Performance on September 12, 2023: Analysts Predict 22.75% Increase. On September 12, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN have a median …On September 5, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $169.41 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was -1.99%, and its shares lost 23.82% of their ...Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - …

Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price.

The stock’s market cap achieved a total value of $6.67 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Repligen Corp. (NASDAQ:RGEN) is 49.48.On average, Wall Street analysts predict that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a ...Oct 18, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Nov 1, 2023 · The stock price rose by $0.27, resulting in a percentage change of +0.61%. While this may seem like a small change, it indicates positive momentum for the company’s stock. Looking ahead, Repligen Corporation is scheduled to release its next financial report on February 15, 2024. With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ...Nov 7, 2023 · Repligen Corp Stock Price History. Repligen Corp’s price is currently up 12.18% so far this month. During the month of November, Repligen Corp’s stock price has reached a high of $152.22 and a low of $126.86. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $110.45. Year to date, Repligen Corp’s stock is ... Apr 25, 2023 · Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%. 4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Quotes Summary Real-Time Live After-Hours Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the …

7.05%. Trailing 12-Months. The Repligen Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 20.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.CureVac N.V. -0.54%. $1.23B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 37 and Quality Score of 71. Comparing Bio Rad Laboratories Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well …One analyst has given the Repligen stock a sell rating, while five others have issued a buy rating on the firm, providing investors with mixed opinions regarding investment in this potentially promising industry player. ... Repligen Corp., a global life sciences company, has been making headlines recently with changes in ratings and price ...... Stock Ideas · Long Ideas · Healthcare. Revisiting Repligen. May 11, 2022 11:31 AM ETRepligen Corporation (RGEN)7 Comments 3 Likes. Another Mountain's ...The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp. (US:RGEN) has 1047 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 71,198,355 shares.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price.

Repligen Corp Bond (US:US759916AB50) has 3 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC) ...Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. ... Stocks Rankings for ...Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ...Instagram:https://instagram. spxehome loan help for single mothershybl dividend2024 betting odds To be eligible to participate in a Job Corps program, applicants must qualify for low-income status under one of five income-related standards: cash assistance, food assistance, earned income, foster child and homelessness.A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. best stocks for swing tradingbest way to invest 5k right now Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ... disney stock dividend Repligen Corp’s Stock Price as of Market Close. As of April 12, 2023, 4:00 PM CST, Repligen Corp’s stock price was $179.70. Repligen Corp is up 5.46% from its previous closing price of $170.39. During the last market session, Repligen Corp’s stock traded between $166.22 and $171.25.UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.